# Beta Agonists {#id}

*This covers the inhaled β-agonists used for bronchodilation. Information on catecholamines and sympathomimetics with activity on β-receptors is covered under [adrenergic vasoactives](adrenergic_drugs.md).*

##Common Features
|Pharmacodynamic Effects|β-agonists|
|--|
|**Resp**|Bronchodilatation, ↓ HPV causing ↑ shunt and potential ↓ O<sub>2</sub> if O<sub>2</sub> is not co-administered.|
|**CVS**|↑ HR (β<sub>1</sub> with higher doses), ↓ BP (β<sub>2</sub> with lower doses) |
|**GU**|UTocolytic.|
|**Metabolic**|Hypokalaemia from β<sub>2</sub> stimulation of Na<sup>+</sup>/K<sup>+</sup> ATPase, hyperglycaemia.|

##Differences
|Property|Salbutamol|Salmeterol|
|--|--|--|
|**Class**|Synthetic sympathomimetic amine|Synthetic sympathomimetic amine|
|**Uses**|Acute asthma, hyperkalaemia|Nocturnal and exercise-induced asthma|
|**Presentation**|MDI (100µg), solution at 2.5-5mg.ml<sup>-1</sup> for nebulisation|MDI|
|**Route of Administration**|Inhaled, IV|Inhaled|
|**Dosing**|1-2 puffs via MDI, 5mg nebulised. 0.5mcg.kg<sup>-</sup>.min<sup>-</sup> as IV infusion.||
|**Onset**|Rapid|Slow|
|**Distribution**|Low protein binding. t<sub>1/2</sub>β 6 hours.|t<sub>1/2</sub>
|**Metabolism**|High first pass hepatic to inactive metabolites||
|**Elimination**|Urinary elimination of active (30%) drug and inactive metabolites|||




---
##References
Peck and Hill
Smith Scarth Sasada